Global Herceptin Biosimilar Market Outlook 2022

Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein.

The global Herceptin Biosimilar market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Herceptin Biosimilar volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Herceptin Biosimilar market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Herceptin Biosimilar Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.


Segment by Type
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
Other


Segment by Application
Hospital & Clinics
Oncology Centers
Other


By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E


By Company
Amgen
AryoGen Biopharma
Biocon
Celltrion
Gedeon Richter
Genor Biopharma
Mabion
Mylan
Roche
The Instituto Vital Brazil